切除修复交叉互补基因1对生存的不同影响。 - Suppr

Suppr

超能文献

Different impact of excision repair cross-complementing group 1 on survival.

作者信息

Panasci Lawrence C

出版信息

J Clin Oncol. 2010 Apr 1;28(10):e163; author reply e164. doi: 10.1200/JCO.2009.26.6619. Epub 2010 Feb 16.

DOI:10.1200/JCO.2009.26.6619

PMID:20159805

Abstract

摘要

相似文献

Different impact of excision repair cross-complementing group 1 on survival.

J Clin Oncol. 2010 Apr 1;28(10):e163; author reply e164. doi: 10.1200/JCO.2009.26.6619. Epub 2010 Feb 16.

Truth about ERCC1 in lung cancer.

J Clin Oncol. 2010 Apr 1;28(10):e162; author reply e164. doi: 10.1200/JCO.2009.26.6270. Epub 2010 Feb 16.

DNA repair by ERCC1 in non-small-cell lung cancer.

N Engl J Med. 2006 Dec 14;355(24):2590; author reply 2591.

ERCC1 and non-small-cell lung cancer.

N Engl J Med. 2007 Jun 14;356(24):2538-40; author reply 2540-1. doi: 10.1056/NEJMc070742.

ERCC1-specific immunostaining in non-small-cell lung cancer.

N Engl J Med. 2007 Oct 11;357(15):1559-61. doi: 10.1056/NEJMc072007.

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Lung Cancer. 2009 Jun;64(3):326-33. doi: 10.1016/j.lungcan.2008.09.002. Epub 2008 Nov 1.

Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.

Expert Rev Mol Diagn. 2007 May;7(3):261-8. doi: 10.1586/14737159.7.3.261.

Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

Clin Cancer Res. 2004 Aug 1;10(15):4939-43. doi: 10.1158/1078-0432.CCR-04-0247.

Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.

Lung Cancer. 2004 Jun;44(3):311-6. doi: 10.1016/j.lungcan.2003.11.019.

Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.

Lung Cancer. 2008 Oct;62(1):105-12. doi: 10.1016/j.lungcan.2008.02.021. Epub 2008 Apr 18.

引用本文的文献

Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancer.

Oncologist. 2014 May;19(5):459-65. doi: 10.1634/theoncologist.2013-0311. Epub 2014 Apr 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Different impact of excision repair cross-complementing group 1 on survival.

作者信息

Panasci Lawrence C

出版信息

J Clin Oncol. 2010 Apr 1;28(10):e163; author reply e164. doi: 10.1200/JCO.2009.26.6619. Epub 2010 Feb 16.

DOI:10.1200/JCO.2009.26.6619

PMID:20159805

Abstract

摘要

相似文献

Different impact of excision repair cross-complementing group 1 on survival.

J Clin Oncol. 2010 Apr 1;28(10):e163; author reply e164. doi: 10.1200/JCO.2009.26.6619. Epub 2010 Feb 16.

Truth about ERCC1 in lung cancer.

J Clin Oncol. 2010 Apr 1;28(10):e162; author reply e164. doi: 10.1200/JCO.2009.26.6270. Epub 2010 Feb 16.

DNA repair by ERCC1 in non-small-cell lung cancer.

N Engl J Med. 2006 Dec 14;355(24):2590; author reply 2591.

ERCC1 and non-small-cell lung cancer.

N Engl J Med. 2007 Jun 14;356(24):2538-40; author reply 2540-1. doi: 10.1056/NEJMc070742.

ERCC1-specific immunostaining in non-small-cell lung cancer.

N Engl J Med. 2007 Oct 11;357(15):1559-61. doi: 10.1056/NEJMc072007.

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Lung Cancer. 2009 Jun;64(3):326-33. doi: 10.1016/j.lungcan.2008.09.002. Epub 2008 Nov 1.

Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.

Expert Rev Mol Diagn. 2007 May;7(3):261-8. doi: 10.1586/14737159.7.3.261.

Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

Clin Cancer Res. 2004 Aug 1;10(15):4939-43. doi: 10.1158/1078-0432.CCR-04-0247.

Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.

Lung Cancer. 2004 Jun;44(3):311-6. doi: 10.1016/j.lungcan.2003.11.019.

Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.

Lung Cancer. 2008 Oct;62(1):105-12. doi: 10.1016/j.lungcan.2008.02.021. Epub 2008 Apr 18.

引用本文的文献

Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancer.

Oncologist. 2014 May;19(5):459-65. doi: 10.1634/theoncologist.2013-0311. Epub 2014 Apr 4.